Telehealth booms as demand for GLP-1s surges and questions mount about safety, oversight

Article excerpt

A 31-year-old Tennessee woman ended up in the hospital vomiting within 24 hours of receiving a GLP-1 weight loss drug through telehealth, one stark example amid the explosive growth of online prescribing for these medications. As demand for GLP-1s like Ozempic and Wegovy skyrockets, telehealth platforms have become a primary distribution channel, but safety concerns are mounting. Doctors and regulators are raising questions about whether patients are being properly screened, monitored, or educated about risks, particularly those without existing relationships with healthcare providers. The case highlights the tension between access and oversight in an industry where profits are soaring but medical oversight remains murky.